225 related articles for article (PubMed ID: 20673702)
1. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
Surendran S
Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of N-acetylaspartic acid induces oxidative stress to contribute in disease pathophysiology.
Surendran S; Bhatnagar M
Int J Neurosci; 2011 Jun; 121(6):305-9. PubMed ID: 21348802
[TBL] [Abstract][Full Text] [Related]
3. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
4. Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Rady PL; Penzien JM; Vargas T; Tyring SK; Matalon R
Eur J Paediatr Neurol; 2000; 4(1):27-30. PubMed ID: 10701101
[TBL] [Abstract][Full Text] [Related]
5. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
[TBL] [Abstract][Full Text] [Related]
6. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
7. Atypical MRI findings in Canavan disease: a patient with a mild course.
Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
[TBL] [Abstract][Full Text] [Related]
8. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
9. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
10. [Canavan disease (aspartoacylase deficiency)].
Kobayashi K; Tsujino S
Ryoikibetsu Shokogun Shirizu; 2001; (36):118-21. PubMed ID: 11596340
[No Abstract] [Full Text] [Related]
11. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
12. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
13. Canavan disease and the role of N-acetylaspartate in myelin synthesis.
Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN
Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192
[TBL] [Abstract][Full Text] [Related]
14. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of aspartoacylase activity in the duodenum of obesity induced diabetes mouse: implications on diabetic neuropathy.
Surendran S; Matalon R; Tyring SK
Biochem Biophys Res Commun; 2006 Jul; 345(3):973-5. PubMed ID: 16707098
[TBL] [Abstract][Full Text] [Related]
16. Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.
Janson CG; Kolodny EH; Zeng BJ; Raghavan S; Pastores G; Torres P; Assadi M; McPhee S; Goldfarb O; Saslow B; Freese A; Wang DJ; Bilaniuk L; Shera D; Leone P
Ann Neurol; 2006 Feb; 59(2):428-31. PubMed ID: 16437572
[TBL] [Abstract][Full Text] [Related]
17. Canavan disease: clinical features and recent advances in research.
Hoshino H; Kubota M
Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939
[TBL] [Abstract][Full Text] [Related]
18. Aspartoacylase gene knockout in the mouse: impact on reproduction.
Surendran S; Szucs S; Tyring SK; Matalon R
Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
[TBL] [Abstract][Full Text] [Related]
19. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
20. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.
Matalon R; Michals K; Sebesta D; Deanching M; Gashkoff P; Casanova J
Am J Med Genet; 1988 Feb; 29(2):463-71. PubMed ID: 3354621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]